Estimaciones de analistas de Wall Street para Anika Therapeutics, Inc. (ANIK): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.17 | ||
| 2026-07-29 | $0.42 | $0.03 | +1300.0% |
| 2026-04-29 | $0.27 | $-0.07 | +485.7% |
| 2026-02-26 | $0.31 | $-0.12 | +348.0% |
| 2025-11-05 | $0.04 | $0.02 | +100.0% |
| 2025-07-30 | $-0.13 | $-0.13 | +0.0% |
| 2025-05-09 | $-0.06 | $0.09 | -166.7% |
| 2025-03-12 | $-0.03 | $-0.01 | -200.0% |
Ratios de valoración
| Precio / Valor contable | 2.02 |
| EV / EBITDA | 97.19 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $103.4M | $113.4M | $105.6M | $114.6M | $130.5M | $147.8M | $113.8M | $120.8M | $119.9M | $112.8M |
| Coste de Ventas | $24.0M | $27.4M | $31.3M | $28.7M | $61.4M | $64.9M | $40.6M | $38.3M | $43.9M | $49.0M |
| Beneficio Bruto | $79.4M | $86.1M | $74.3M | $85.9M | $69.0M | $82.9M | $73.2M | $82.5M | $76.0M | $63.8M |
| I+D | $10.7M | $18.8M | $18.2M | $16.7M | $23.4M | $27.3M | $18.3M | $21.8M | $25.5M | $25.8M |
| Generales y Administrativos | $18.0M | $21.5M | $34.3M | $35.0M | $60.1M | $74.1M | $51.2M | $59.9M | $55.6M | $49.1M |
| Gastos Operativos | $28.7M | $40.3M | $52.5M | $51.6M | $97.3M | $80.3M | $69.5M | $81.7M | $81.1M | $74.9M |
| Beneficio Operativo | $50.6M | $45.7M | $21.7M | $34.2M | -$28.3M | $2.6M | $3.7M | $844000 | -$5.1M | -$11.1M |
| EBITDA | $54.3M | $50.0M | $27.7M | $40.2M | -$1.0M | -$4.2M | $18.8M | $17.4M | $5.4M | -$3.6M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | $800000 | 0 | 0 | 0 | ||
| Beneficio Antes de Impuestos | $50.9M | $46.2M | $23.2M | $36.1M | -$28.6M | $2.4M | $4.3M | $3.2M | -$2.8M | -$9.3M |
| Impuestos | $18.3M | $14.4M | $4.5M | $8.9M | -$4.6M | -$1.7M | $2.1M | $6.6M | $6.1M | $672000 |
| Beneficio Neto | $32.5M | $31.8M | $18.7M | $27.2M | -$24.0M | $4.1M | -$14.9M | -$82.7M | -$56.4M | -$10.9M |
| BPA | $2.22 | $2.18 | $1.30 | $1.93 | $-1.69 | $0.29 | $-1.02 | $-5.64 | $-3.83 | $-0.76 |
| BPA Diluido | $2.15 | $2.11 | $1.27 | $1.89 | $-1.69 | $0.28 | $-1.02 | $-5.64 | $-3.83 | $-0.76 |
| Acciones en Circulación (Diluidas) | $15.1M | $15.1M | $14.7M | $14.4M | $14.2M | $14.6M | $14.6M | $14.7M | $14.7M | $14.3M |
Precio
| Precio | $21.03 |
| Capitalización | $281M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ANIX · APYX · ARAY · AVR · LNSR · LUCD · MXCT
Explorar sector: Healthcare · Medical - Specialties
Más secciones de ANIK: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones